The evolution of preclinical Alzheimer’s disease: Implications for prevention trials

By Reisa A. Sperling, Elizabeth C. Mormino, Keith A. Johnson. Neuron, 2014

679 citations recorded by the source corpus.

As the field begins to test the concept of preclinical neurodegenerative disease, the hypothetical stage of disease when the pathophysiological process has begun in the brain but clinical symptoms are not yet manifest, a number of intriguing questions have already arisen. In particular, in preclinical Alzheimer’s disease (AD), the temporal relationship of amyloid markers to markers of neurodegeneration and their relative utility in the prediction of cognitive decline among clinically normal older individuals remains to be fully elucidated. Secondary prevention trials in AD have already begun in both genetic-at-risk and amyloid-at-risk cohorts, with several more trials in the planning stages, that should provide critical answers about whether intervention at this very early stage of disease can truly bend the curve of clinical progression.

Subfields: Cognitive Neuroscience, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/3059d33c900f580d135bfd87af5e2b46dfbc3e5c